Literature DB >> 16186811

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.

Carlos Vaccaro1, Jinchun Zhou, Raimund J Ober, E Sally Ward.   

Abstract

We have engineered the Fc region of a human immunoglobulin G (IgG) to generate a mutated antibody that modulates the concentrations of endogenous IgGs in vivo. This has been achieved by targeting the activity of the Fc receptor, FcRn, which serves through its IgG salvage function to maintain and regulate IgG concentrations in the body. We show that an IgG whose Fc region was engineered to bind with higher affinity and reduced pH dependence to FcRn potently inhibits FcRn-IgG interactions and induces a rapid decrease of IgG levels in mice. Such FcRn blockers (or 'Abdegs,' for antibodies that enhance IgG degradation) may have uses in reducing IgG levels in antibody-mediated diseases and in inducing the rapid clearance of IgG-toxin or IgG-drug complexes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186811     DOI: 10.1038/nbt1143

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  145 in total

1.  Accelerated Blood Clearance of Antibodies by Nanosized Click Antidotes.

Authors:  Weston J Smith; Guankui Wang; Hanmant Gaikwad; Vivian P Vu; Ernest Groman; David W A Bourne; Dmitri Simberg
Journal:  ACS Nano       Date:  2018-12-05       Impact factor: 15.881

2.  Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates.

Authors:  Mauro Acchione; Hyewon Kwon; Claudia M Jochheim; William M Atkins
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

3.  Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys.

Authors:  Amita Datta-Mannan; Derrick R Witcher; Jirong Lu; Victor J Wroblewski
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

4.  Monoclonal antibodies directed against human FcRn and their applications.

Authors:  Gregory J Christianson; Victor Z Sun; Shreeram Akilesh; Emanuele Pesavento; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

5.  X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn.

Authors:  Adam R Mezo; Vandana Sridhar; John Badger; Paul Sakorafas; Vicki Nienaber
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

Review 6.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

7.  Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor.

Authors:  Jaspreet Singh Jaggi; Jorge A Carrasquillo; Surya V Seshan; Pat Zanzonico; Erik Henke; Andrew Nagel; Jazmin Schwartz; Brad Beattie; Barry J Kappel; Debjit Chattopadhyay; Jing Xiao; George Sgouros; Steven M Larson; David A Scheinberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 8.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

Review 9.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

10.  Modulation of IgG-FcRn interactions to overcome antibody-mediated inhibition of nerve regeneration.

Authors:  Gang Zhang; Jianxin Lin; Sameera Ghauri; Kazim A Sheikh
Journal:  Acta Neuropathol       Date:  2017-05-30       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.